- Home
- MNPR vs BARK Comparison
MNPR vs BARK Comparison
Compare MNPR & BARK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- BARK
- Stock Information
- Founded
- MNPR 2014
- BARK 2011
- Country
- MNPR United States
- BARK United States
- Employees
- MNPR N/A
- BARK N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- BARK Department/Specialty Retail Stores
- Sector
- MNPR Health Care
- BARK Consumer Discretionary
- Exchange
- MNPR Nasdaq
- BARK Nasdaq
- Market Cap
- MNPR 244.1M
- BARK 244.9M
- IPO Year
- MNPR 2019
- BARK N/A
- Fundamental
- Price
- MNPR $39.59
- BARK $1.23
- Analyst Decision
- MNPR Strong Buy
- BARK Buy
- Analyst Count
- MNPR 5
- BARK 2
- Target Price
- MNPR $59.50
- BARK $2.50
- AVG Volume (30 Days)
- MNPR 27.1K
- BARK 768.0K
- Earning Date
- MNPR 05-08-2025
- BARK 06-02-2025
- Dividend Yield
- MNPR N/A
- BARK N/A
- EPS Growth
- MNPR N/A
- BARK N/A
- EPS
- MNPR N/A
- BARK N/A
- Revenue
- MNPR N/A
- BARK $490,256,000.00
- Revenue This Year
- MNPR N/A
- BARK $3.12
- Revenue Next Year
- MNPR N/A
- BARK $7.76
- P/E Ratio
- MNPR N/A
- BARK N/A
- Revenue Growth
- MNPR N/A
- BARK N/A
- 52 Week Low
- MNPR $1.72
- BARK $1.01
- 52 Week High
- MNPR $54.30
- BARK $2.56
- Technical
- Relative Strength Index (RSI)
- MNPR 57.10
- BARK 31.53
- Support Level
- MNPR $26.06
- BARK $1.29
- Resistance Level
- MNPR $40.90
- BARK $1.44
- Average True Range (ATR)
- MNPR 4.78
- BARK 0.10
- MACD
- MNPR 0.64
- BARK -0.00
- Stochastic Oscillator
- MNPR 84.89
- BARK 10.71
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About BARK BARK Inc.
BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.